We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung Adenocarcinoma

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2010 by China Medical University Hospital.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01249053
First Posted: November 29, 2010
Last Update Posted: November 29, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
China Medical University Hospital
November 24, 2010
November 29, 2010
November 29, 2010
August 2010
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung Adenocarcinoma
Not Provided
Optic atrophy type 1(OPA1) is a nuclear dynamin-related GTPase, targeted to the inner mitochondrial membrane, which plays a role in mitochondrial fusion. Mitochondria fusion is associated with process of apoptosis. . OPA1 plays an important role in the mitochondrial bioenergetics and mitochondrial networks. The changes in mitochondrial shape and mitochondrial bioenergetics may be cause of the disease. In this study, we investigate the expression of OPA1 in lung adenocarcinoma (LADC) cells and tissue.
Not Provided
Observational
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample
Between January 2006 and December 2008, we will retrospectively enroll 100 consecutive LADC patients who were admitted to the Department of Thoracic Surgery of China Medical University Hospital.
Lung Adenocarcinoma
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
100
Not Provided
Not Provided

Inclusion Criteria:

  • We will collect paraffin blocked resected lung tissue samples from stage I~IIIa non-small cell lung cancer patients (age, 40~80 years old) who received lobectomy of the affected lung.

Exclusion Criteria:

  • History of uremia, other malignant disease, and liver cirrhosis
  • History of pneumonia and pulmonary tuberculosis
  • History of long period of medications.
Sexes Eligible for Study: All
25 Years to 85 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Taiwan
 
 
NCT01249053
DMR99-IRB-062
No
Not Provided
Not Provided
Fang Hsin-Yuan/Director, China Medical University Hospital
China Medical University Hospital
Not Provided
Not Provided
China Medical University Hospital
November 2010